

LISTING AND AMENDMENT OF THE CLAIMS:

1. (Currently amended) A soft gelatin capsule containing a pharmaceutical formulation comprising at least one omega-3 polyunsaturated fatty acid in free acid form characterised in that the capsule comprises Type A gelatin ~~extracted by an extraction process comprising acid pre-treatment of a collagen source.~~
2. (Original) A soft gelatin capsule as claimed in Claim 1 wherein formulation comprises 5, 8, 11, 14, 17-eicosapentaenoic acid (or "EPA").
3. (Original) A soft gelatin capsule as claimed in Claim 2 wherein EPA is present in an amount of at least about 50 wt % of the formulation.
4. (Currently amended) A soft gelatin capsule as claimed in Claim 2 ~~or Claim 3~~ wherein EPA is present in an amount of between from about 50 wt % to about 60 wt % of the formulation.
5. (Previously presented) A soft gelatin capsule as claimed in Claim 2 wherein EPA is present in an amount of at least about 90 wt % of the formulation.
6. (Previously presented) A soft gelatin capsule as claimed in Claim 1 wherein the formulation comprises 4, 7, 10, 13, 16, 19-docosahexaenoic acid (or "DHA").
7. (Previously presented) A soft gelatin capsule as claimed in Claim 6 wherein DHA is present in an amount of between from about 20 wt % to about 30 wt % of the formulation.
8. (Previously presented) A soft gelatin capsule as claimed in Claim 1 comprising between from about 100mg to about 2000mg of said formulation.

Serial Number: 10/587,201
Attorney Docket: SACH3001/ESS

9. (Previously presented) A soft gelatin capsule as claimed in Claim 8 comprising about 500mg of said formulation.
10. (Previously presented) A soft gelatin capsule as claimed in Claim 8 comprising about 1000mg of said formulation.
11. (Canceled)
12. (Canceled)
13. (Previously presented) A soft gelatin capsule as claimed in Claim 1 wherein the gelatin comprises porcine gelatin.
14. (Previously presented) A soft gelatin capsule as claimed in Claim 1 wherein the gelatin comprises bovine gelatin.
15. (Previously presented) A soft gelatin capsule as claimed in Claim 1 wherein the gelatin comprises fish gelatin.
16. (Previously presented) A soft gelatin capsule as claimed in Claim 1 wherein the wall of the capsule consists of a single layer.
17. (Previously presented) A soft gelatin capsule as claimed in Claim 1 wherein the capsule delays release of the formulation until after passage through the stomach.
18. (Previously presented) A soft gelatin capsule as claimed in Claim 1 wherein the capsule delays release of the formulation until after passage beyond the pancreatic duct in the duodenum.

19. (Previously presented) A soft gelatin capsule as claimed in Claim 17 wherein the capsule is coated with at least one enteric material.
20. (Previously presented) A soft gelatin capsule as claimed in Claim 19 wherein at least one enteric material is integrated within the gelatin of the capsule.
21. (Previously presented) A soft gelatin capsule as claimed in Claim 19 wherein the or at least one enteric material is a neutral polyacrylate polymer.
22. (Previously presented) A soft gelatin capsule as claimed in Claim 20 wherein the or at least one enteric material is poly(ethylacrylate-methylmethacrylate).
23. (Canceled)
24. (Canceled)
25. (Currently amended) A process for the manufacture of a soft gelatin capsule containing a pharmaceutical formulation comprising at least one omega-3 polyunsaturated fatty acid in free acid form, said process comprising encapsulating said pharmaceutical formulation in Type A gelatin ~~extracted by an extraction process comprising acid pre-treatment of a collagen source.~~
26. (Canceled)
27. (Canceled)
28. (Canceled)
29. (Canceled)

30. (Currently amended) A method of treatment or prophylaxis of a condition selected from chronic inflammatory conditions, hyperlipidaemia, hypertriglyceridaemia, asthma, bipolar disorder and neoplastic disease wherein said neoplastic disease is treatable with omega-3 polyunsaturated fatty acid in combination with an antineoplastic agent selected from the group consisting of methotrexate, dactinomycin, fluorouracil, bleomycin, etoposide, taxol, vincristine, doxorubicin, cisplatin, daunorubicin and VP-16, said method comprising administering a therapeutically effective amount of a pharmaceutical formulation comprising at least one omega-3 polyunsaturated fatty acid in free acid form in the form of a plurality of soft gelatin capsules containing a pharmaceutical formulation comprising at least one omega-3 polyunsaturated fatty acid in free acid form characterized in that the capsule comprises Type A gelatin gelatine ~~extracted by an extraction process comprising acid pre-treatment of a collagen source.~~

31. (Previously presented) A method as claimed in Claim 30 wherein the omega-3 polyunsaturated fatty acid in free acid form comprises EPA.

32. (Canceled)

33. (Canceled)

34. (Canceled)